

QUALITY OF VMPS – UPDATE ON PICS

REGIONAL WEBINAR –VMPS FOCAL POINTS AFRICAN COUNTRIES, 23RD FEBRUARY 2022

Jean-Pierre Orand French agency for veterinary medicinal products, OIE Collaborating centre for VMPs jean-pierre.orand@anses.fr



Introduction





Introduction



Ensuring the Quality of Veterinary Medicinal Products (VMPs) is an essential and basic requirement for the good governance of VMPs.

Use of non good quality VMPs presents risks:

- For animal health: inefficient medicines
- For human health:
 - Risk of residues in food
 - Inefficient vaccines could have impact on zoonosis outbreak
- For environment : pollution

Marketing Authorisation dossier





Administrative Part: Summary of the dossier

Part 2: Pharmaceutical quality Part

Constituents, Manufacturing process, Control of starting materials, tests carried out at intermediate stages of the process, finished product ...

Part 3: Safety and residues tests Part

Toxicology tests (single dose toxicity, repeat dose, effects on reproduction), user safety, environmental risk assessment ... (chemical products), administration of one dose, overdose, repeated administration, effects on reproductive performance... (immunological products)

Part 4: Efficacy tests

Preclinical and clinical trials...

Pharmaceutical Quality Part





Qualitative and Quantitative Particulars of the Constituents

Description of the Manufacturing Method

Control of Starting Materials

Control Tests Carried out at intermediate stages of the Manufacturing Process

Tests on the Finished Product

Stability Test

Other Information

Quality at all steps of VMPs life



VICH GLs

GDP

Ethic Code

MARKETING AUTHORISATION

- Definition of specifications
- Descriptions of the methods of manufacturing, control, etc.
- Establishments involved in the manufacturing...
- Benefit/risk balance

MANUFACTURE

- Good manufacturing practices
- GMP certificate for establishments:

Quality management

- Management of anomalies
- Testing for product release
- Complaints management

MARKETING

- Good distribution practices
- Cold chain
- Advertising
- Quality defects
- Pharmacovigilance

USERS

Veterinary practitioners Farmers Animal owners

Pharmacovigilance Quality defects

OIE Manual

GMP

GPVceP

BPG



PICS





PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME

8



PICS: Organisation / Missions

The **Pharmaceutical Inspection Co-operation Scheme** is an **international instrument** between countries and pharmaceutical inspection authorities, which provide together an active and constructive co-operation in the field of **GMP**.

PIC/S' mission is "to lead the international development, implementation and maintenance of harmonised Good Manufacturing Practice (GMP) standards and quality systems of inspectorates in the field of medicinal products."

http://picscheme.org/




GOALS




PICS: Current members





Benefits of PICS members









Guides, recommendations & Quality systems (GMP guide + API + GDP)

Expert Circles



Aim:

Develop draft guidance documents & Training in specialised field



- **✓** APIs
- ✓ Controlling Cross Contamination in Shared Facilities
- ✓ Human Blood, Tissues, Cells & ATMPs
- ✓ Quality Risk Management
- ✓ Good Distribution Practices

Working Groups



- 1. Revision of Annex 1 (joint WG with EMA and WHO)
- 2. Revision of Annex 2
- 3. Harmonisation of Classification of Deficiencies
- 4. Data Integrity
- 5. Controlling Cross-Contamination in Shared Facilities
- 6. GCP & GVP
- 7. Revision of PI 006
- 8. Unique Facility Identifiers (UFI)
- 9. Inspector Travel Safety
- 10. Veterinary Medicinal Products
- 11. Quality Defects


- 12. Informants
- 13. Revision of Blood guidance documents
- 14. Aide Memoire on Tissues and Cellular Therapy Products Inspections
- 15. Computerised Systems
- 16. Revision of Accession Guidelines and related documents
- 17. Third Party Funding
- Revision of the PIC/S Aide Memoire on QRM Implementation
- 19. ICH Q12 Training Material
- 20. PIC/S Inspection Reliance
- 21. Remote Assessment

PIC/S and Working group on VMPs



A new Working Group on VMP launched in 2018:

Circle on VMP



the WG on VMP

PIC/S and Working group on VMPs



Main topics of the 2020-2025 road map for the WG on VMP:



Quality System requirements



Aim:

Adopt a common standard for quality system requirements – to ensure consistency in inspection standards between National Pharmaceutical Inspectorates.

In return this facilitates mutual recognition of those Inspectorates.

- Quality Improvement & Corrective / Preventive Action
- Complaints
- Issue & Withdrawal of Licences and GMP certificates
- Handling Suspected Quality Defects & Rapid Alert System

- Quality Manual
- Administrative Structure
- Organisation and Management
- Documentation and Change Control
- Records
- Inspection Procedures
- Inspection Resources
- Internal Audit

PIA: Inspectorates Academy





- A unique virtual tool for proposing harmonised training material and qualification process for GMP inspectors
- A system defined by inspectors for inspectors
- Containing training modules validated by experts belonging to PIC/S Participating Authorities
- With a regular update on its contents
- Available 24h/ 24, 365 days a year



Web based educational centre

Standardises GMP training at international level – recognised qualification


Delivers general or advanced GMP training

Is a platform for discussion / sharing among regulators

A single point of access to all PIC/S training

Partners





PICS Contact



Address: PIC/S Secretariat

14 rue du Roveray

CH - 1207 GENEVA

Tel: +41.22 738 92 16

Email: info@picscheme.org

Web site: www.picscheme.org





Conclusion





Conclusion



- Ensuring quality of Veterinary medicinal products is essential.
- Appropriate legislation and Staff (trained inspectors, laboratory capacities) are needed.
 - Efficient systems of Authorisation (VMP and companies)
 - Transparency and communication
 - Efficient Inspectorate body with appropriate power
 - The possibility to survey both the legal and illegal market

are essential as well as:

The capacity of prosecution and recalling products